SYRA 📈 Syra Health Class A Common - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
SYRA: Digital Health, Behavioral Health Services, Patient Care, Healthcare Workforce
Syra Health Corp., a healthcare services company, provides solutions in behavioral and mental health, population health, digital health, health education, and healthcare workforce in the United States. The company Syrenity, behavioral and mental health application that identifies and prevents the progression of negative factors that can influence individuals' mental health, by offering targeted assignments, education, monitoring symptoms, and providing interventions; digital health products, such as SyraBot that automates manual tasks to streamline healthcare professional care, aiding patients in identifying health warning signs, encouraging therapy and medical regimens, and space for patients to share personal information; and CarePlus, a customizable templates, e-prescribing, laboratory integration, and patient portal access. It offers analytics as a service which includes data collection, traditional to advanced analytics, predictive analytics, risk stratification, intervention analytics, spatial analytics gap analysis, analytics workforce public policy, and research; epidemiology, and health equity analytics solutions. In addition, the company offers medical communications, patient education, and healthcare training; and recruits nurses and allied health professionals for long-term fixed contract positions at hospitals and healthcare facilities. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana. Web URL: https://www.syrahealth.com
Additional Sources for SYRA Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SYRA Stock Overview
Market Cap in USD | 4m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Facilities |
IPO / Inception | 2023-09-29 |
SYRA Stock Ratings
Growth 5y | -69.6% |
Fundamental | -9.80% |
Dividend | - |
Rel. Strength Industry | -2952 |
Analysts | - |
Fair Price Momentum | 0.32 USD |
Fair Price DCF | - |
SYRA Dividends
No Dividends PaidSYRA Growth Ratios
Growth Correlation 3m | 1.6% |
Growth Correlation 12m | -63.2% |
Growth Correlation 5y | -62.3% |
CAGR 5y | -81.23% |
CAGR/Mean DD 5y | -1.16 |
Sharpe Ratio 12m | 0.49 |
Alpha | -90.03 |
Beta | 1.03 |
Volatility | 241.05% |
Current Volume | 80.4k |
Average Volume 20d | 257.5k |
What is the price of SYRA stocks?
As of December 21, 2024, the stock is trading at USD 0.38 with a total of 80,436 shares traded.
Over the past week, the price has changed by -6.34%, over one month by -2.41%, over three months by -22.18% and over the past year by -66.49%.
As of December 21, 2024, the stock is trading at USD 0.38 with a total of 80,436 shares traded.
Over the past week, the price has changed by -6.34%, over one month by -2.41%, over three months by -22.18% and over the past year by -66.49%.
Is Syra Health Class A Common a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Syra Health Class A Common is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -9.80 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SYRA as of December 2024 is 0.32. This means that SYRA is currently overvalued and has a potential downside of -15.79%.
Neither. Based on ValueRay Fundamental Analyses, Syra Health Class A Common is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -9.80 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SYRA as of December 2024 is 0.32. This means that SYRA is currently overvalued and has a potential downside of -15.79%.
Is SYRA a buy, sell or hold?
Syra Health Class A Common has no consensus analysts rating.
Syra Health Class A Common has no consensus analysts rating.
What are the forecast for SYRA stock price target?
According to ValueRays Forecast Model, SYRA Syra Health Class A Common will be worth about 0.4 in December 2025. The stock is currently trading at 0.38. This means that the stock has a potential downside of -5.26%.
According to ValueRays Forecast Model, SYRA Syra Health Class A Common will be worth about 0.4 in December 2025. The stock is currently trading at 0.38. This means that the stock has a potential downside of -5.26%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 1.8 | 373.7% |
Analysts Target Price | - | - |
ValueRay Target Price | 0.4 | -5.3% |